Many patients experience slower progress after nine to twelve months of therapy, although timing varies depending on adherence, dose optimization, and underlying metabolic conditions
Precision addiction medicine: fMRI results may reveal neural signatures predicting who benefits from GLP-1 therapy, opening the door for AI models that stratify patient populations by responsiveness
A baseline blood chemistry panel and medical history will also be done for the patient safety profile of semaglutide, as risky health conditions such as congestive heart failure, renal impairment, liver disease, and pancreatitis may disallow a patient from taking the drug
But patients need more than just the medication
It feeds good gut bacteria and may help with digestion
Products like Trulicity and Victoza have established themselves as essential therapies in endocrinology protocols, often replacing older medications like sulfonylureas